Effect of Paricalcitol Over Vessel Wall: Pleiotropic Analogues Vitamin D Effects
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 50
- 主要终点
- Prevention on vessels progression based on paricalcitol intake.
研究概览
简要总结
To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.
详细描述
Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged between 50 and 75 years.
- •Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD).
- •Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.
- •Plasma concentrations of 25 (OH) vitamin D <30 ng/ml.
- •Without vitamin D supplementation for 3 months before the study.
- •Serum P> 3.8 mg / dl.
- •Serum Ca> 9.8 mg / dl.
- •No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease).
- •No exclusion criteria for the use of contrast.
排除标准
- •Allergic reaction to sulfur hexafluoride.
- •Recent unstable cardiac symptoms.
- •Patients with recent coronary intervention (<7 days)
- •Patients with class III and IV heart failure or severe arrhythmias.
- •Severe pulmonary hypertension.
研究组 & 干预措施
Treatment
Patient will take one pill of paricalcitol a day.
干预措施: Paricalcitol (Drug)
结局指标
主要结局
Prevention on vessels progression based on paricalcitol intake.
时间窗: participants will be followed for the duration of whole study, an expected average of 1 year
Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.
次要结局
未报告次要终点